Skip to main content
Premium Trial:

Request an Annual Quote

FDA Panel to Meet About Epigenomics' PMA for Colorectal Cancer Test

NEW YORK (GenomeWeb News) – A US Food and Drug Administration panel is tentatively set to meet in four months to discuss Epigenomics’ colorectal cancer screening test, the company said today.

FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to meet on March 25, 2014 over Epigenomics’ premarket approval submission for its Epi proColon test. The company completed its submission in January, and in February, FDA granted Epigenomics’ application priority review status.

Earlier this month, the company announced flat revenues for its third quarter.